View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Comment
July 15, 2019updated 12 Jul 2022 12:28pm

Trials data suggests Cosentyx from Novartis will change psoriasis market

Cosentyx is set to change the landscape of the psoriasis market following results published by Novartis from a phase II study,

On June 26, Novartis published data from their latest Phase II study in psoriasis patients.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Results show that Cosentyx (secukinumab) modulates gene expression, leading to substantial improvement of inflammation, as early as 12 weeks post-treatment.

In addition to this, Cosentyx also induces rapid and sustained suppression of additional cytokines such as IL-23 and IL-17F in addition to the known IL-17A suppression. With this dual inhibition mechanism, GlobalData expects that Cosentyx will change the landscape of the psoriasis market, which could give Novartis a competitive advantage over other marketed therapies, posing a threat to the IL-23 class of drugs.

In the randomised, double-blinded, placebo-controlled Phase II clinical study, four assessments were performed to measure the effectiveness of Cosentyx in psoriasis patients.

This includes clinical assessments using Psoriasis Area and Severity Index (PASI)/Investigator’s Global Assessment (IGA) and Dermatology Life Quality Index (DLQI), skin biopsies, ex vivo T cell activation, and peripheral blood mononuclear cells as biomarkers.

Patients were segmented into two arms; in the Cosentyx-treated arm, patients were given 300mg of Cosentyx for four weeks in the first month and then monthly doses for up to 12 weeks. Additionally, 12 patients were treated in the placebo arm.

After 12 weeks of treatment, Cosentyx reversed plaque histopathology in 56.5% of treated patients compared with 0% of placebo-controlled patients. Cosentyx did not affect the ex vivo T cell activation, which is consistent and favourable for a long-term safety profile.

Interestingly, transcriptome analysis was also performed, which showed that Cosentyx can modulate gene expression in psoriasis patients.

Results show that Cosentyx induces a rapid and sustained suppression of additional cytokines including IL-23 and IL-17F. Suppression of the IL-23/IL-17 axis by Cosentyx was evident at week 1 and continued through week 12, including reductions in the upstream cytokine IL-23, drug target IL-17A, and downstream inflammatory targets including beta-defensin 2. Furthermore, suppression of the IL-23/IL-17 axis by Cosentyx at week 4 was associated with clinical and histological responses at week 12.

With this data in mind, Novartis has demonstrated strong results in its Phase II study, which could give the company an advantage in a fiercely competitive psoriasis market.

As Cosentyx acts as a dual inhibitor, suppressing IL-17 and IL-23 expression in psoriasis-treated patients, the drug could dominate other IL-17 inhibitors such as Taltz (ixekizumab) and Siliq (brodalumab) as well as IL-23 inhibitors such as Tremfya (guselkumab) and Ilumya (tildrakizumab), persuading physicians and dermatologists to steer away from IL-23 monoclonal antibody treatment.

This data might also come at a bad time for AbbVie’s enhanced efforts to market its newly approved IL-23 inhibitor, Skyrizi (risankizumab).

Overall, Novartis’ new data could turn physicians’ and dermatologists’ attention in the direction of Cosentyx and give it the boost it needs to push for top-selling status.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena